Acanthosis nigricans

Last updated
Acanthosis nigricans
Acanthosis-nigricans4.jpg
Acanthosis nigricans on the armpit
Specialty Dermatology

Acanthosis nigricans is a cutaneous finding characterized by brown-to-black, velvety hyperpigmentation of the skin, most often affecting body folds such as the posterior neck, axillae, groin and umbilicus. [1] It is strongly associated with insulin resistance and hyperinsulinaemia, including in type 2 diabetes and metabolic syndrome. Excess insulin activates insulin and insulin-like growth factor signalling pathways, stimulating proliferation of keratinocytes and fibroblasts and producing the characteristic plaques. [2]

Contents

Acanthosis nigricans may also occur in hereditary syndromes, as a reaction to medications or as a paraneoplastic syndrome associated with internal malignancy. In children, it is an important clinical marker of metabolic and cardiometabolic risk. [3]

Signs and symptoms

Acanthosis nigricans presents as hyperpigmented, velvety plaques with poorly defined borders. Common sites include:

Lesions are usually asymptomatic, though mild pruritus may occur. [1]

Causes

Acanthosis nigricans arises from several distinct mechanisms. It most commonly reflects insulin resistance and is frequently associated with type 2 diabetes, obesity and endocrine disorders such as hypothyroidism, acromegaly, polycystic ovary syndrome and Cushing's disease. [4] [5] It may also be inherited, medication-related or associated with internal malignancy. Review articles describe acanthosis nigricans primarily as a marker of systemic metabolic dysfunction rather than a primary skin disease. [6] [7] [8]

Acral acanthotic anomaly

Acral acanthotic anomaly is a localized variant affecting the elbows, knees, knuckles and dorsal feet. It occurs in otherwise healthy individuals, and its etiology is unknown. [9] [10] It is not associated with internal disease. [11]

Familial (Type I)

Familial acanthosis nigricans is an autosomal dominant condition presenting at birth or during childhood. [12] [13]

Endocrine (Type II)

Endocrine-associated acanthosis nigricans occurs in metabolic or hormonal disorders that alter glucose or androgen levels. [14] : 978 

Common associated conditions include:

This form usually has a gradual onset and often occurs in people who are also obese. [15] : 676 

Malignancy (Type V)

Malignant acanthosis nigricans is a paraneoplastic syndrome most often associated with gastrointestinal adenocarcinomas, particularly gastric cancer. [8] [16] Less commonly, it occurs with malignancies of the breast, ovary, prostate, thyroid, lung or lymphoid tissues.

It may precede, accompany or follow a cancer diagnosis. [13] : 506  Mucosal involvement is more common than in benign forms. [17] Additional findings may include multiple seborrhoeic keratoses, skin tags and tripe palms. [15] : 676 

Obesity and pseudoacanthosis nigricans (Type III)

In young people, acanthosis nigricans is a visible marker of insulin resistance. Elevated insulin stimulates epidermal proliferation. [18] Insulin resistance syndromes may be classified as type A (HAIR-AN) or type B. [14] : 978 

Most cases are obesity-associated and otherwise idiopathic. This pattern is more common in darker-skinned individuals and is sometimes termed pseudoacanthosis nigricans. [12] : 86 

Facial involvement may appear as a horizontal forehead band or as periorbital or perioral hyperpigmentation. [19]

Pediatric associations

In children and adolescents, acanthosis nigricans commonly co-occurs with overweight and obesity and functions as a clinical marker of insulin resistance and increased cardiometabolic risk. [3] Longitudinal studies show higher rates of subsequent metabolic syndrome. [20] Cross-sectional studies link acanthosis nigricans with low serum 25-hydroxyvitamin D levels. [21]

Medications associated with acanthosis nigricans include nicotinic acid, glucocorticoids, combined oral contraceptives and growth hormone therapy. [12] : 86  A systematic review has reported additional agents, including insulin, hormonal therapies, antineoplastic medications and certain biologics. [22]

Pathophysiology

Acanthosis nigricans results from activation of growth factor receptor pathways, most commonly insulin-mediated stimulation of insulin-like growth factor receptor on keratinocytes and fibroblasts. [2] Hyperinsulinaemia may also displace IGF-1 from its binding proteins, amplifying epidermal proliferation.

Contributing mechanisms include:

Sweat, friction and occlusion may accentuate lesion development in predisposed areas. [2]

Diagnosis

Acanthosis nigricans is typically diagnosed clinically based on its characteristic velvety hyperpigmentation and distribution. [14] A skin biopsy is rarely needed but, when performed, shows hyperkeratosis, papillomatosis and mild basal hyperpigmentation. [12] : 87 

Evaluation aims to identify associated conditions. Investigations may include:

Classification

A conventional clinical distinction separates:

A broader classification proposed in 1994 groups acanthosis nigricans into benign, malignant, obesity-associated, drug-induced, acral, unilateral and mixed or syndromic variants. [23]

Treatment

Management of acanthosis nigricans (AN) generally involves evaluating for and addressing any associated underlying condition rather than treating the skin changes alone. When AN occurs in the setting of obesity, insulin resistance or type 2 diabetes mellitus, improvement in metabolic status may be followed by gradual softening or lightening of the lesions, although the degree of change varies. [24]

Drug-induced AN may improve after reduction or discontinuation of the causative medication when clinically appropriate. Reported associations include systemic corticosteroids, high-dose nicotinic acid and certain hormonal therapies. [24]

In malignancy-associated AN, particularly that linked to gastrointestinal adenocarcinomas, regression of the cutaneous changes has been observed following treatment of the underlying tumour, though this is not universal. [25] Sudden onset, rapid progression or mucosal involvement have been described in malignant forms and may prompt further evaluation. [24]

Topical and procedural therapies

Topical therapies are used mainly for cosmetic reasons. Small clinical studies have reported improvement with topical retinoids, urea preparations and other keratolytic agents, although evidence remains limited and results vary among individuals. [24] Topical treatment does not modify the underlying cause of AN.

Procedural interventions, including fractional carbon dioxide (CO2) laser and various chemical peels, have been explored in pilot studies and small comparative trials. A randomized controlled trial involving 38 participants reported that fractional CO2 laser resulted in greater reduction of lesion severity compared with retinoic-acid peel; however, the study was short-term and limited in size. [26] Procedural therapies generally require specialised equipment, and availability and cost may limit use.

Systemic therapies

Because many cases of AN are associated with metabolic dysfunction, improvement in weight or insulin sensitivity may coincide with changes in the skin. Metformin, which is widely used for insulin resistance and type 2 diabetes, has been reported in case series and observational studies to coincide with improvement in AN; however, high-quality randomized trials with AN as a primary outcome are not available. [27]

Glucagon-like peptide-1 (GLP-1) receptor agonists, used for obesity and diabetes, have also been associated with improvement in some individuals with AN in observational reports, likely secondary to changes in metabolic status. These medications are not used specifically to treat AN, and evidence remains indirect. [28]

Prognosis

The prognosis depends on the underlying cause. Obesity- and insulin resistance–related forms often improve with weight loss and metabolic control. Drug-induced cases typically resolve with withdrawal of the causative agent. Hereditary variants may persist. Malignancy-associated acanthosis nigricans may regress following tumour treatment. [12] : 87 

History

Acanthosis nigricans was first described by Paul Gerson Unna in 1889. [29]

Epidemiology

Acanthosis nigricans is reported worldwide, with prevalence varying by age, ethnicity and underlying metabolic risk. In clinic- and community-based samples of people with obesity and insulin resistance, reported prevalence ranges from about 7% to over 70%, depending on the population and diagnostic criteria used. [7] [8]

Higher rates are consistently observed among individuals of African, Hispanic/Latino, Native American and some Asian ancestries, reflecting both genetic susceptibility and a higher burden of obesity and metabolic syndrome in many of these populations. [7] [3] In children and adolescents, the prevalence of acanthosis nigricans has risen alongside increasing rates of overweight and obesity and is common in pediatric cohorts with insulin resistance or metabolic syndrome. [3] [20]

Across studies, acanthosis nigricans is more frequent among people with higher body mass index, increased waist circumference and biochemical markers of insulin resistance. [7] [3] [21]

References

  1. 1 2 James, William D.; Elston, Dirk; Treat, James R.; Rosenbach, Misha A.; Neuhaus, Isaac (2020). Andrews' Diseases of the Skin: Clinical Dermatology (13th ed.). Elsevier. pp. 502–504. ISBN   978-0-323-54753-6.
  2. 1 2 3 4 5 Higgins, S. P.; Freemark, M.; Prose, NS (2008). "Acanthosis nigricans: a practical approach to evaluation and management". Dermatology Online Journal. 14 (9): 2. doi:10.5070/D37MF6G290. PMID   19061584.
  3. 1 2 3 4 5 Pollock, Samara; et al. (2022). "Acanthosis nigricans in the pediatric population: a narrative review". Pediatric Medicine. 5: 42. doi: 10.21037/pm-21-70 . PMC   9678372 . PMID   36420374.
  4. ↑ "Acanthosis nigricans – Symptoms and causes". Mayo Clinic. Retrieved 2021-08-13.
  5. ↑ "What is Acanthosis Nigricans?". WebMD. Retrieved 2021-08-13.
  6. ↑ Parmar, S. (2025). "A comprehensive review of acanthosis nigricans: pathogenesis, clinical manifestation and management". Recent Advances in Inflammation & Allergy Drug Discovery. 19 (2): 135–145. doi:10.2174/0127722708314530240919054410. PMID   40667590.
  7. 1 2 3 4 Karadağ, A. S. (2018). "Acanthosis nigricans and the metabolic syndrome". Clinical Dermatology. 36 (1): 48–53. doi:10.1016/j.clindermatol.2017.09.008. PMID   29241752.
  8. 1 2 3 Popa, M. L.; et al. (2019). "Acanthosis nigricans: to be or not to be afraid". Oncology Letters. 17 (5): 4133–4138. doi:10.3892/ol.2018.9736. PMC   6444334 . PMID   30944606.
  9. ↑ Schwartz, Robert A. (2007). "Acral acanthosis nigricans (acral acanthotic anomaly)". Journal of the American Academy of Dermatology. 56 (2): 349–350. doi:10.1016/j.jaad.2006.09.027. PMID   17224380.
  10. ↑ Schwartz, Robert A. (1981). "Acral acanthotic anomaly (AAA)". Journal of the American Academy of Dermatology. 5 (3): 345–346. doi:10.1016/S0190-9622(81)80155-7. PMID   7263979.
  11. ↑ Tilgen, W. (2009). Burgdorf, WHC (ed.). Braun-Falco's Dermatology (3rd ed.). Springer. pp. 1340–1347. ISBN   978-3-540-29312-5.
  12. 1 2 3 4 5 6 7 Fitzpatrick, Thomas B. (2005). Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology (5th ed.). McGraw-Hill Medical. pp. 86–87. ISBN   978-0-07-144019-6.
  13. 1 2 James, William D. (2006). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders Elsevier. p. 506. ISBN   978-0-7216-2921-6.
  14. 1 2 3 4 Habif, Thomas P. (2009). Clinical Dermatology (5th ed.). Mosby Elsevier. pp. 968–979. ISBN   978-0-323-04852-1.
  15. 1 2 Bolognia, Jean L. (2007). Dermatology (2nd ed.). Mosby. p. 676. ISBN   978-1-4160-2999-1.
  16. 1 2 Rigel, DS; Jacobs, MI (1980). "Malignant acanthosis nigricans: a review". Journal of Dermatologic Surgery and Oncology. 6 (11): 923–927. doi:10.1111/j.1524-4725.1980.tb01003.x. PMID   6257767.
  17. ↑ Schnopp, C.; Baumstark, J. (2007). "Oral acanthosis nigricans". New England Journal of Medicine. 357 (9): e10. doi:10.1056/NEJMicm062917. PMID   17761587.
  18. ↑ "Insulin Resistance and Acanthosis Nigricans in Kids". Nueces County Medical Society. Archived from the original on 2018-04-12. Retrieved 2020-03-01.
  19. ↑ Verma, Shyam; et al. (2016). "Facial acanthosis nigricans and its association with BMI, waist circumference and insulin resistance". Indian Dermatology Online Journal. 7 (6): 498–503. doi: 10.4103/2229-5178.193898 . PMC   5134163 . PMID   27990384.
  20. 1 2 Taren, D.; et al. (2023). "Diet and acanthosis nigricans over two years in children". Nutrients. 15 (12): 2718. doi: 10.3390/nu15122718 . PMC   10302045 . PMID   37375623.
  21. 1 2 Isart, F. A. (2022). "Acanthosis nigricans is a strong predictor of low blood calcidiol levels in children and adolescents". Metabolic Syndrome and Related Disorders. 20 (9): 509–516. doi:10.1089/met.2022.0005. PMID   35834574.
  22. ↑ Mourad, A. I.; Haber, R. M. (2021). "Drug-induced acanthosis nigricans: a systematic review and new classification". Dermatologic Therapy. 34 (2) e14794. doi:10.1111/dth.14794. PMID   33480113.
  23. ↑ Schwartz, Robert A. (1994). "Acanthosis nigricans". Journal of the American Academy of Dermatology. 31 (1): 1–19. doi:10.1016/S0190-9622(94)70128-8. PMID   8021347.
  24. 1 2 3 4 Rogers, R S (2017). "Current treatment options for acanthosis nigricans". Clinical, Cosmetic and Investigational Dermatology. 10: 423–429. doi: 10.2147/IJN.S139215 . PMC   5577798 . PMID   28860760.
  25. ↑ Curth, H O (1963). "Significance of acanthosis nigricans". Archives of Dermatology. 88 (1): 67–76. doi:10.1001/archderm.1963.01590250069011 (inactive 16 November 2025). PMID   13968919.{{cite journal}}: CS1 maint: DOI inactive as of November 2025 (link)
  26. ↑ Gnanasuriyan, R; Shanmugam, S (June 2025). "Comparison of the Effectiveness of Fractional Carbon Dioxide Laser and Retinoic Acid Peel in the Treatment of Acanthosis Nigricans: A Randomized Controlled Trial". Cureus. 17 (6) e86047. doi: 10.7759/cureus.86047 . PMC   12261829 . PMID   40666598.
  27. ↑ Hamdani, G; Birch, M P; Mason, A R (August 2020). "Oral metformin for treating dermatological diseases: A systematic review". Journal of Drugs in Dermatology. 19 (8): 780–787. PMID   32845585.
  28. ↑ Elmasry, M F; Ali, Z (2025). "Metformin: Old drug, new therapeutic potential in the skin? A brief narrative review". Advances in Therapy. 42 (8). Springer: 3606–3620. doi:10.1007/s12325-025-03256-x. PMC   12020976 . PMID   40291350.
  29. ↑ Levine, Norman (2008). Nordlund, James J. (ed.). The Pigmentary System: Physiology and Pathophysiology (2nd ed.). Blackwell Publishing. p. 907. ISBN   978-1-4051-2034-0.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.